<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111807">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01648283</url>
  </required_header>
  <id_info>
    <org_study_id>201203105</org_study_id>
    <nct_id>NCT01648283</nct_id>
  </id_info>
  <brief_title>CYP2B6 Polymorphisms in Methadone</brief_title>
  <official_title>Role of CYP2B6 Polymorphisms in Methadone Metabolism and Clearance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study will determine if genetic variation in CYP2B6 affects how the body
      metabolizes methadone.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effects of methadone on healthy volunteers</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>This outcome will be measured by blood draws taken during the study days and follow-ups. This research study will determine if genetic variation in CYP2B6 affects how the body metabolizes methadone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Methadone and bupropion concentration</measure>
    <time_frame>Up to 96 hours</time_frame>
    <description>This outcome will be measured by blood and urine collections, as well as dark pupil measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methadone and bupropion clearance from the body</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>This outcome will be measured by blood and urine collections, as well as dark pupil measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral methadone and bupropion absorption</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>This outcome will be measured by blood and urine collections, as well as dark pupil measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of CYP2B6*6 hetero or homozyge genotype on the above primary and secondary outcomes</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>This outcome will be measured by blood and urine collections, as well as dark pupil measurement.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Methadone arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous racemic methadone HCl, 6.0 mg bolus
Oral deuterated racemic methadone HCl, 11 mg capsule (IND#58,511) CYP2B6 is phenotyped by the clearance oral racemic bupropion 150mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>racemic methadone HC1</intervention_name>
    <description>IV racemic Methadone HC1 6 mg oral d5-methadon HC1 11 mg</description>
    <arm_group_label>Methadone arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral deuterated racemic methadone HCl,</intervention_name>
    <description>11 mg capsule once</description>
    <arm_group_label>Methadone arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Each subject must meet all of the following criteria:

          -  18-50 yr old

          -  CYP2B6*1/*1, CYP2B6*1/*6 or CYP2B6*6/*6 genotype

          -  Good general health with no remarkable medical conditions

          -  BMI &lt; 33

          -  Provided informed consent

        Exclusion Criteria:

        Subjects will not be enrolled if any of the following criteria exist:

          -  Known history of liver or kidney disease

          -  Use of prescription or non prescription medications, herbals or foods known to be
             metabolized by or affect CYP2B6

          -  Females who are pregnant or nursing

          -  Known history of drug or alcohol addiction (prior or present addiction or treatment
             for addiction)

          -  Direct physical access to and routine handling of addicting drugs in the regular
             course of duty (this is a routine exclusion from studies of drugs with addiction
             potential)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan Kharasch, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University Schoool of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 16, 2016</lastchanged_date>
  <firstreceived_date>June 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>methadone polymorphisms</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
